ERBB2 and neoplasm: Prosigna is based on the PAM50 assay, incorporating tumor size and an estimate of molecular class (e.g., basal-like, HER2-enriched, luminal A, luminal B) to separate patients into low-, intermediate-, and high-risk groups based on a score8.